Akari Therapeutics Plc (AKTX) is listed on NASDAQ in Pharmaceutical Stocks. It is $11.10, +23.20%, with a $1.7T market cap. RSI is 65.9, near overbought. The latest reported quarter missed estimates. Insiders were net buyers across the listed trades.
Technical Analysis
RSI (14) 65.9 Near Overbought
Market Cap $1.7T
Volume 137.2K
Fundamentals — 10-Q Q2 2026
Revenue --
Net Income $-19.3M
EPS $0.00
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Gaslightwala Abizer | CEO | Buy | 21,000 | $0.93 | $19,540 | 2025 Aug 25 |
| Gaslightwala Abizer | President & CEO | Buy | 6,146 | $1.16 | $7,120 | 2025 Jun 24 |
| Gaslightwala Abizer | President & CEO | Buy | 10,000 | $1.20 | $12,000 | 2025 Jun 20 |
| Gaslightwala Abizer | President & CEO | Buy | 15,000 | $1.20 | $18,000 | 2025 Jun 17 |
| Cohen Mark S | Director | Buy | 1,055,600 | $0.19 | $200,564 | 2015 Sep 18 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
Take AKTX further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put AKTX in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Akari Therapeutics Plc next reports.
Set alerts on AKTX
Get notified when Akari Therapeutics Plc hits your price targets or technical conditions are met.
Get Started Free